A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-κB pathway

A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-κB pathway

Interleukin-1 receptor-associated kinase 4 (IRAK4) is a pivotal enzyme in the Toll-like receptor (TLR)/MYD88 dependent signaling pathway, which is highly activated in rheumatoid arthritis tissues and activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL). Inflammatory responses followed by...

Full description

Bibliographic Details
Main Authors: Sae-Bom Yoon, Hyowon Hong, Hee-Jong Lim, Ji Hye Choi, Yoon Pyo Choi, Seong Wook Seo, Hyuk Woo Lee, Chong Hak Chae, Woo-Kyu Park, Hyun Young Kim, Daeyoung Jeong, Tran Quang De, Chang-Seon Myung, Heeyeong Cho
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Drug discovery
IRAK4
PIM1
NF-κB pathway
Rheumatoid arthritis
ABC-DLBCL
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383522004956

Internet

http://www.sciencedirect.com/science/article/pii/S2211383522004956

Similar Items